The VLA-4–binding Ile-Leu-Asp-Val (ILDV) moiety is an another notable peptide drug candidate that can competitively inhibit VCAM-1–mediated cell recruitment during atherosclerosis. This evidence concerns the gene VCAM1 and atherosclerosis.